TY - JOUR T1 - Biochemical Recurrence of Prostate Cancer: Initial Results with [<sup>18</sup>F]PSMA-1007 PET/CT JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 632 LP - 635 DO - 10.2967/jnumed.117.196329 VL - 59 IS - 4 AU - Frederik L. Giesel AU - Leon Will AU - Claudia Kesch AU - Martin Freitag AU - Christophe Kremer AU - Jonas Merkle AU - Oliver C. Neels AU - Jens Cardinale AU - Boris Hadaschik AU - Markus Hohenfellner AU - Klaus Kopka AU - Uwe Haberkorn AU - Clemens Kratochwil Y1 - 2018/04/01 UR - http://jnm.snmjournals.org/content/59/4/632.abstract N2 - Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007–positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P &lt; 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007–positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR. ER -